Literature DB >> 8892032

The effect of enzyme therapy in a patient with Gaucher disease type III.

D K Bosman1, C E Hollak, J M Aerts, H D Bakker.   

Abstract

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8892032     DOI: 10.1007/bf01799852

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


× No keyword cloud information.
  3 in total

1.  Treatment of Gaucher's disease.

Authors:  C E Hollak; J M Aerts; M H van Oers
Journal:  N Engl J Med       Date:  1993-05-27       Impact factor: 91.245

2.  Replacement therapy for inherited enzyme deficiency--macrophage-targeted glucocerebrosidase for Gaucher's disease.

Authors:  N W Barton; R O Brady; J M Dambrosia; A M Di Bisceglie; S H Doppelt; S C Hill; H J Mankin; G J Murray; R I Parker; C E Argoff
Journal:  N Engl J Med       Date:  1991-05-23       Impact factor: 91.245

3.  Marked elevation of plasma chitotriosidase activity. A novel hallmark of Gaucher disease.

Authors:  C E Hollak; S van Weely; M H van Oers; J M Aerts
Journal:  J Clin Invest       Date:  1994-03       Impact factor: 14.808

  3 in total
  1 in total

1.  Neurological outcome of a patient with Gaucher disease type III treated by enzymatic replacement therapy.

Authors:  D Dobbelaere; S Sukno; S Defoort-Dhellemmes; M D Lamblin; C Largillière
Journal:  J Inherit Metab Dis       Date:  1998-02       Impact factor: 4.982

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.